Search papers, labs, and topics across Lattice.
1
0
0
4
It is suggested that the ICI + Antiangio-Ab + Chemo triple regimen may offer potential benefits for patients with driver gene-negative nonsquamous NSCLC and the two ICI-containing regimens was not significant.